Clinical Trial Update: 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study [Phase 2]

View source ↗

Summary

The LUNAR study is a Phase 2 trial evaluating 177Lu-PSMA therapy before stereotactic body radiotherapy in oligometastatic or recurrent prostate cancer; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Lutetium-177 PSMA-617 (lutetium Lu-177 PSMA-617)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING